Literature DB >> 6310573

Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin.

D Panicali, S W Davis, R L Weinberg, E Paoletti.   

Abstract

Recombinant vaccinia viruses containing the cloned hemagglutinin (HA) gene from influenza virus were constructed. The biological activity of these poxvirus vectors was demonstrated both in vitro and in vivo. Expression of HA in cells infected with recombinant vaccinia was detected by using specific anti-HA antiserum and 125I-labeled protein A, showing that HA synthesized under the regulation of vaccinia virus was antigenic. Immunization of rabbits with these recombinant poxviruses resulted in the production of antibodies reactive with authentic influenza HA as detected by radioimmunoassay, by inhibition of HA erythrocyte agglutination, and by neutralization of influenza virus infectivity. The production of antibodies directed against influenza HA suggested that the HA gene expressed in vaccinia is immunogenic. These data indicate the potential of genetically engineered poxviruses for use as generic live vaccine vehicles that have both human and veterinary applications.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6310573      PMCID: PMC384256          DOI: 10.1073/pnas.80.17.5364

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  13 in total

1.  Construction and characterization of new cloning vehicles. III. Derivatives of plasmid pBR322 carrying unique Eco RI sites for selection of Eco RI generated recombinant DNA molecules.

Authors:  F Bolivar
Journal:  Gene       Date:  1978-10       Impact factor: 3.688

2.  Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus.

Authors:  D Panicali; S W Davis; S R Mercer; E Paoletti
Journal:  J Virol       Date:  1981-03       Impact factor: 5.103

3.  A restriction map of the bacteriophage T4 genome.

Authors:  P H O'Farrell; E Kutter; M Nakanishi
Journal:  Mol Gen Genet       Date:  1980

4.  Mapping and identification of the vaccinia virus thymidine kinase gene.

Authors:  D E Hruby; L A Ball
Journal:  J Virol       Date:  1982-08       Impact factor: 5.103

5.  Rat insulin genes: construction of plasmids containing the coding sequences.

Authors:  A Ullrich; J Shine; J Chirgwin; R Pictet; E Tischer; W J Rutter; H M Goodman
Journal:  Science       Date:  1977-06-17       Impact factor: 47.728

6.  Molecular genetics of vaccinia virus: demonstration of marker rescue.

Authors:  E Nakano; D Panicali; E Paoletti
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

7.  Vaccinia virus: a selectable eukaryotic cloning and expression vector.

Authors:  M Mackett; G L Smith; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

8.  Construction and characterization of new cloning vehicles. II. A multipurpose cloning system.

Authors:  F Bolivar; R L Rodriguez; P J Greene; M C Betlach; H L Heyneker; H W Boyer; J H Crosa; S Falkow
Journal:  Gene       Date:  1977       Impact factor: 3.688

9.  Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA.

Authors:  J P Weir; G Bajszár; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

10.  Gene composition of high-yielding influenza vaccine strains obtained by recombination.

Authors:  M Baez; P Palese; E D Kilbourne
Journal:  J Infect Dis       Date:  1980-03       Impact factor: 5.226

View more
  57 in total

1.  Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine.

Authors:  Reuben K Soi; Fred R Rurangirwa; Travis C McGuire; Paul M Rwambo; James C DeMartini; Timothy B Crawford
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

Review 2.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

3.  Investigating Viruses during the Transformation of Molecular Biology.

Authors:  Bernard Moss
Journal:  J Biol Chem       Date:  2017-01-30       Impact factor: 5.157

4.  Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus.

Authors:  J F Rodriguez; R Janeczko; M Esteban
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

Review 5.  Reflections on the early development of poxvirus vectors.

Authors:  Bernard Moss
Journal:  Vaccine       Date:  2013-04-10       Impact factor: 3.641

6.  Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity.

Authors:  C J Langford; S J Edwards; G L Smith; G F Mitchell; B Moss; D J Kemp; R F Anders
Journal:  Mol Cell Biol       Date:  1986-09       Impact factor: 4.272

Review 7.  Vaccinia virus: a suitable vehicle for recombinant vaccines?

Authors:  C Kaplan
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

8.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Authors:  M Mackett; G L Smith; B Moss
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

9.  Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.

Authors:  E Paoletti; B R Lipinskas; C Samsonoff; S Mercer; D Panicali
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

10.  Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence.

Authors:  Aodhnait S Fahy; Richard H Clark; Emily F Glyde; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2008-10       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.